Allarity (ALLR) Therapeutics announced that its Board of Directors has authorized a share repurchase program, allowing for the repurchase of up to $5 million of the Company’s common stock through February 28, 2026. The decision underscores the Company’s confidence in its future trajectory and dedication to delivering value to both patients and shareholders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Biotech Alert: Searches spiking for these stocks today
- Allarity announces dismissal of securities class action lawsuit
- Allarity to begin enrollments for Phase 2 protocol to advance stenoparib
- Allarity announces expansion of Phase 2 trial on stenoparib
- Allarity filed a Form 8-K regarding settlement agreement with SEC
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue